Press release
Investigation announced for Long-Term Investors in Penumbra, Inc. (NYSE: PEN)
An investigation on behalf of current long term investors in Penumbra, Inc. (NYSE: PEN) shares.
Investors who are current long term investors in Penumbra, Inc. (NYSE: PEN) shares, have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554.
The investigation by a law firm for current long term investors in NYSE: PEN stocks follows a lawsuit filed against Penumbra, Inc. over alleged securities laws violations. The investigation on behalf of current long term investors in NYSE: PEN stocks, concerns whether certain Penumbra directors are liable in connection with the allegations made in that lawsuit.
According to that complaint filed in the U.S. District Court for the Northern District of California the plaintiff alleges that the Defendants failed to disclose to investors that the Jet 7 Xtra Flex had known design defects that made it unsafe for its normal use, that Penumbra did not adequately address the risk of Jet 7 Xtra Flex causing serious injury and deaths, which had in fact already occurred, that the Jet 7 Xtra Flex was likely to be recalled due to its safety issues, and that as a result, Penumbra’s public statements as set forth above were materially false and misleading at all relevant times.
Those who purchased shares of Penumbra, Inc. (NYSE: PEN) have certain options and should contact the Shareholders Foundation.
Contact:
Shareholders Foundation, Inc.
Michael Daniels
3111 Camino Del Rio North - Suite 423
92108 San Diego
Phone: +1-(858)-779-1554
Fax: +1-(858)-605-5739
mail@shareholdersfoundation.com
About:
The Shareholders Foundation, Inc. is a professional portfolio monitoring and settlement claim filing service, , which does research related to shareholder issues and informs investors of securities class actions, settlements, judgments, and other legal related news to the stock/financial market. Shareholders Foundation, Inc. is in contact with a large number of shareholders and offers help, support, and assistance for every shareholder. The Shareholders Foundation, Inc. is not a law firm. Referenced cases, investigation, and/or settlements are not filed/reached and/or related to Shareholders Foundation. The information is provided as a public service. It is not intended as legal advice and should not be relied upon.
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Investigation announced for Long-Term Investors in Penumbra, Inc. (NYSE: PEN) here
News-ID: 2274268 • Views: …
More Releases from Shareholders Foundation
ALERT: Lawsuit filed for Investors who SOLD shares of Sina Corporation (formerly …
An investor, who sold shares of Sina Corporation (formerly NASDAQ: SINA) in the merger between Seina Corporation and TuSimple Holdings, Inc, filed a lawsuit over alleged violations of Federal Securities Laws by Sina Corporation (formerly NASDAQ: SINA in connection with certain allegedly false and misleading statements made.
If you sold a significant amount of shares of Sina Corporation (formerly NASDAQ: SINA) between October 13, 2020 and March 22, 2021, you have…
Lawsuit Alert: Investors who lost money with shares of Fluor Corporation (NYSE: …
An investor, who purchased shares of Fluor Corporation (NYSE: FLR), filed a lawsuit alleged violations of Federal Securities Laws by Fluor Corporation in connection with certain allegedly false and misleading statements.
Investors who purchased shares of Fluor Corporation (NYSE: FLR) have certain options and for certain investors are short and strict deadlines running. Deadline: November 14, 2025. NYSE: FLR investors should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779…
Investigation announced for Long-Term Investors in shares of Sable Offshore Corp …
An investigation was announced for long-term investors in shares of Sable Offshore Corp. (NYSE: SOC) concerning potential breaches of fiduciary duties by certain directors of Sable Offshore Corp.
Investors who are current long term investors in Sable Offshore Corp. (NYSE: SOC) shares, have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554.
The investigation by a law firm for current long term investors in…
Lawsuit filed for Investors who lost money with shares of Lantheus Holdings, Inc …
An investor, who purchased shares of Lantheus Holdings, Inc. (NASDAQ: LNTH), filed a lawsuit over alleged violations of Federal Securities Laws by Lantheus Holdings, Inc. in connection with certain allegedly false and misleading statements.
Investors who purchased shares of Lantheus Holdings, Inc. (NASDAQ: LNTH) have certain options and for certain investors are short and strict deadlines running. Deadline: November 10, 2025. NASDAQ: LNTH investors should contact the Shareholders Foundation at mail@shareholdersfoundation.com…
More Releases for Penumbra
Intracranial Aneurysm Market Is Booming So Rapidly | Penumbra, Phenox, Acandis
The Global Intracranial Aneurysm Market Size is estimated at $2.1 Billion in 2025 and is forecast to register an annual growth rate (CAGR) of 8.9% to reach $4.5 Billion by 2034.
The latest study released on the Global Intracranial Aneurysm Market by USD Analytics Market evaluates market size, trend, and forecast to 2034. The Intracranial Aneurysm market study covers significant research data and proofs to be a handy resource document for…
Microcatheter Market Is Expanding So Quickly | Terumo, Penumbra, Integer
USD Analytics Market recently introduced Global Microcatheter Market study with 65+ pages in-depth overview, describing about the Product / Industry Scope and elaborates market outlook and status (2024-2032). The market Study is segmented by key regions which is accelerating the marketization. At present, the market is developing its presence and some of the key players from the complete study are Boston Scientific, Medtronic, Terumo, Cook Medical, Stryker, Merit Medical, Asahi…
Neurothrombectomy Devices Market Is Booming So Rapidly | Penumbra, Cerenovus, Ac …
The "Neurothrombectomy Devices Market" intelligence report, just published by USD Analytics Market, covers a micro-level study of important market niches, product offers, and sales channels. To determine market size, potential, growth trends, and competitive environment, the Neurothrombectomy Devices Market provides dynamic views. Both primary and secondary sources of data were used to generate the research, which has both qualitative and quantitative depth. Several of the major figures the study featured…
Investigation announced for Investors in shares of Penumbra, Inc. (NYSE: PEN)
Penumbra, Inc. is under investigation concerning potential securities laws violations in connection with certain financial statements.
Investors who purchased shares of Penumbra, Inc. (NYSE: PEN), have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554.
The investigation by a law firm focuses on whether a series of statements by Penumbra, Inc. regarding its business, its prospects and its operations were materially false and misleading at…
Neurovascular Devices Market | Johnson & Johnson (Depuy), Medtronic, Stryker, Te …
Global Neurovascular Devices Market: Key Trends
The rising number of ischemic strokes and brain aneurysm is one of the prominent factors expected to encourage the growth of the global neurovascular devices market in the next few years. In addition, a substantial rise in the demand for surgical processes with minimum invasion and technological developments in this field are anticipated to fuel the growth of the overall market in the coming…
Occlusion Devices Market 2017 - 2025 : Stryker Corporation, Penumbra, Abbott, Ca …
Occlusion devises Market: Snapshot
Occlusion devices are popularly used in cardiology for correcting the conditions caused by obstructions of blood flow in the coronary artery. These medical devices have emerged as a more effective option than anticoagulation therapy in treating the strokes caused by atrial fibrillation. For instance, of late, the market is witnessing promising avenues from the marked therapeutic efficacy of occlusion devices to reduce the risk of embolic stroke…
